Abivax SA surged in early trading following reports that Eli Lilly and Company is preparing a $17.5 billion bid for the biopharmaceutical firm. The news sparked significant market interest in the French-based company, which specializes in immune-modulating therapies.
- Eli Lilly is reportedly preparing a $17.5 billion bid for Abivax SA.
- Abivax’s market cap prior to the news was approximately $12.3 billion.
- The proposed acquisition implies a 42% premium over Abivax’s pre-announcement valuation.
- Abivax’s lead drug, ABX464, is in late-stage trials for Crohn’s disease and ulcerative colitis.
- The deal would expand Eli Lilly’s focus into autoimmune and inflammatory disease treatments.
- Abivax shares rose over 35% on speculation of the potential acquisition.
Abivax SA's stock rallied sharply on January 12, 2026, after financial sources reported that Eli Lilly and Company was evaluating a proposed acquisition valued at $17.5 billion. The potential deal would mark one of the largest pharmaceutical mergers in recent years and signals Eli Lilly’s strategic push into novel immunology treatments. The transaction, if finalized, would significantly expand Eli Lilly’s pipeline in autoimmune and inflammatory disease therapeutics, where Abivax has several late-stage candidates in development. The $17.5 billion figure represents a substantial premium over Abivax’s current market capitalization, which stood at approximately $12.3 billion prior to the announcement. This valuation implies a roughly 42% increase in enterprise value, reflecting investor confidence in Abivax’s pipeline, particularly its lead compound ABX464, which is under investigation for Crohn’s disease and ulcerative colitis. The company’s proprietary platform targeting the immune system’s regulatory pathways has drawn interest from major players in the biopharma sector. Markets reacted swiftly, with Abivax shares rising over 35% in early trading, while Eli Lilly’s stock remained relatively stable, suggesting market participants view the bid as a strategic move rather than an immediate threat to Eli Lilly’s financial position. Analysts note that the acquisition would allow Eli Lilly to strengthen its presence in the $100 billion global autoimmune therapeutics market and accelerate its growth beyond diabetes and obesity-focused drugs. The potential deal remains speculative, as no formal offer has been submitted, and negotiations are reportedly in early stages. However, the surge in Abivax's valuation underscores the premium investors place on innovative biotech platforms with strong clinical data. The outcome will likely hinge on regulatory scrutiny, competitive dynamics, and the ability of both companies to align on integration and development timelines.